New hope for advanced cancer: OBI-902 trial launches

NCT ID NCT07124117

Recruiting now Disease control Sponsor: OBI Pharma, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called OBI-902 in people with advanced solid tumors that have not responded to standard treatments. The trial has three parts: first, finding the safest dose; second, checking how well it works in certain cancers; and third, comparing doses to pick the best one for larger studies. About 147 adults will take part, and the main goals are to see if the drug is safe and can shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

China Medical University Hospital
RECRUITING

Taichung, 404327, Taiwan
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States
Scripps Green Hospital
RECRUITING

La Jolla, California, 92037, United States
Shuang Ho Hospital
ACTIVE_NOT_RECRUITING

Taipei, Zhonghe, 23561, Taiwan
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Wan Fan Hospital
RECRUITING

Taipei, Wenshan, 116, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.